All In Biotech

Drug Trial Radar · NCT07645287

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

A Phase 2 Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Aug 2027

Study completion Apr 2033

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in virologically suppressed people with HIV-1 (PWH) in treatment Group 1, 2 and 3 at Week 35. In Part B the goal of the study is to compare the effectiveness of switching to the study drugs, GS-3242 and LEN versus continuing B/F/TAF in Groups 4 and 3 at Week 26. The primary objective of part A is to evaluate the efficacy of switching to intramuscular (IM) GS-3242 plus IM LEN versus continuing on B/F/TAF PWH who are virologically suppressed in treatment Groups 1, 2, and 3 at Week 35 and Part B is to evaluate the efficacy of switching to IM GS-3242 plus IM LEN versus continuing on B/F/TAF in PWH who are virologically suppressed in Treatment Groups 4 and 3 at Week 26.

Conditions

  • HIV-1-infection

Interventions

  • GS-3242 TabletDrug

    Administered orally

  • GS-3242 InjectionDrug

    Administered intramuscularly (IM)

  • Lenacapavir TabletDrug

    Administered orally

  • Lenacapavir InjectionDrug

    Administered IM

  • B/F/TAFDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmTime frame: Week 35
  2. Part B: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot AlgorithmTime frame: Week 26

Locations

59 sites in 4 countries. Site status is shown where the registry gives one.

  • Pueblo Family Physicians

    Phoenix, Arizona · Not yet recruiting

  • Pacific Oak Medical Group

    Beverly Hills, California · Recruiting

  • Ruane Clinical Research Group Inc.

    Los Angeles, California · Recruiting

  • Optimus Medical Group

    San Francisco, California · Recruiting

  • University of California San Francisco, Community and Clinical Research Center

    San Francisco, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Mills Clinical Research

    West Hollywood, California · Not yet recruiting

  • University of Colorado Clinical and Translational Research Center

    Aurora, Colorado · Not yet recruiting

  • Vivent Health

    Denver, Colorado · Recruiting

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida · Recruiting

  • CAN Community Health Fort Lauderdale

    Fort Lauderdale, Florida · Recruiting

  • Midway Immunology and Research Center

    Ft. Pierce, Florida · Recruiting

  • AIDS Healthcare Foundation -Coconut Grove

    Miami, Florida · Recruiting

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida · Recruiting

  • Orlando Immunology Center, PA

    Orlanda, Florida · Recruiting

  • AHF - Pensacola

    Pensacola, Florida · Recruiting

  • CAN Community Health Inc.

    Sarasota, Florida · Recruiting

  • Triple O Research Institute, PA

    West Palm Beach, Florida · Recruiting

  • Emory University Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia · Recruiting

  • Metro Infectious Disease Consultants, P.L.L.C.

    Decatur, Georgia · Recruiting

  • Mercer University, Department of Internal Medicine

    Macon, Georgia · Recruiting

  • Chatham County Health Department

    Savannah, Georgia · Recruiting

  • Be Well Medical Center

    Berkeley, Michigan · Recruiting

  • KC CARE Health Center

    Kansas City, Missouri · Recruiting

  • Southampton Community Healthcare

    St Louis, Missouri · Recruiting

  • ID care

    Hillsborough, New Jersey · Recruiting

  • Saint Michael's Medical Center

    Newark, New Jersey · Recruiting

  • South Jersey Infectious Disease

    Somers Point, New Jersey · Recruiting

  • AXCES Research Group, LLC

    Sante Fe, New Mexico · Recruiting

  • Brooklyn Clinical Research

    Brooklyn, New York · Recruiting

  • NewYork-Presbyterian Queens

    Flushing, New York · Recruiting

  • NYU Langone Health Vaccine Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Not yet recruiting

  • The Brody School of Medicine at East Carolina University

    Greenville, North Carolina · Not yet recruiting

  • Rosedale Health and Wellness

    Huntersville, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Not yet recruiting

  • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center

    Philadelphia, Pennsylvania · Recruiting

  • Central Texas Clinical Research

    Austin, Texas · Recruiting

  • St. Hope Foundation

    Bellaire, Texas · Recruiting

  • Prism Health North Texas

    Dallas, Texas · Recruiting

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.